SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

The keys to heart health are relatively straightforward: Maintain a healthy weight. Reduce alcohol consumption. Quit smoking.

Synopsis: In a recently issued final written decision, the Patent Trial and Appeal Board (the “Board”) found all challenged ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere ...

Your challenge this week? Take a hike! Whether it’s a rugged mountain trail, a peaceful local forest path, or even a city ...

Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar ...

Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...

In a challenging market environment, Atossa Genetics Inc . (NASDAQ:ATOS) stock has touched a 52-week low, reaching a price ...

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

Atossa Therapeutics (ATOS) issued the following statement in response to the Patent Trial and Appeal Board’s, PTAB, final written decision in ...

These bank stocks are all $50 billion or more in market value with a 3% yield or higher.